As with many other types of cancer, several factors determine how fast kidney cancer can spread. Your age, overall health and the type of kidney cancer all play a role in whether the disease is fast- or slow-growing.
Results from the CheckMate 214 clinical trial show that combined therapy with two immunotherapy drugs, nivolumab and ipilimumab, can be very effective in the treatment of renal cell carcinoma, the most common type of kidney cancer.